Adverse Effects of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Type of TKI is associated with increased risk for cardiovascular and arteriothrombotic events.

Tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in chronic myeloid leukemia (CML), for which complete cytogenetic and major molecular remissions are expectations of therapy, but TKIs are associated with long-term toxicity.

To assess TKI-related toxicity in this setting, investigators retrospectively analyzed cardiovascular (CV) and arteriothrombotic (AT) events reported in single-center prospective trials involving a total of 531 newly diagnosed chronic-phase CML patients (median age, 48 years) treated with front-line imatinib (400 mg or 800 mg), nilotinib, dasatinib, or ponatinib. At baseline, 51% of patients had prior hypertension, 32% were obese, 23% had history of smoking, 15% had diabetes, 8% had coronary artery d…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Adverse Effects of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Topics

Reviewing Author